<p>HCC827, HCC827/GR and HCC827/ER2 cells were treated with the indicated concentrations of gefitinib and erlotinib for 72 h in medium containing 1% FBS. Cell viability and IC<sub>50</sub> values were determined using the MTT assay.</p
<p>(<b>A</b>) BT474, JIMT-1 and MCF7-GFPLC3 cells were treated for 24 h, 72 h and 168 h, respectivel...
<p>The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant cell line H1975 wer...
<p>A) Immunoblot of c-Met<sup>-</sup> cell lines Huh7 and Hep3B and c-Met<sup>+</sup> cell lines MHC...
<p>Cells were treated with the indicated doses of gefitinib, erlotinib, afatinib, or AUY922 for 72 h...
<p>(A) Parental HCC78 and HCC78-TR cells were treated with gefitinib as a single-agent for 3 days an...
<p>(<b>A</b>) Cell viability was assessed following treatment with PF-228 at varying doses for 48 ho...
<p>(A) Phospho-RTK (top) and phospho-kinase (bottom) array analyses performed on untreated parental ...
<p>IC50 for treatment with erlotinib, gefitinib or vandetanib in parental CALU-3 and HCT116 cell lin...
<p>(A) Parental PC9 and gefitinib-resistant PC9 (PC9-GR) cells were treated with gefitinib at the in...
<p>Cells were treated with CX-4945 (5 µM), gefitinib (1 µM), and erlotinib (1 µM) or a combination o...
<p>Cell proliferation in AG1478 (left), gefitinib (middle) and erlotinib (right) was measured by SRB...
<p>(A) Erlotinib-resistant cells (H1650ER) were established by long-term exposure to increasing conc...
<p>HN5 (red), FaDu (blue) and SCC-25 (green) cells were seeded in 96-well plates and treated with th...
<p>A) Representative dose-effect curve plots of HCC827 and HCC4006 parental cell lines to the indica...
PDAC cells were treated with the indicated concentrations of gefitinib for 6 days and cell viability...
<p>(<b>A</b>) BT474, JIMT-1 and MCF7-GFPLC3 cells were treated for 24 h, 72 h and 168 h, respectivel...
<p>The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant cell line H1975 wer...
<p>A) Immunoblot of c-Met<sup>-</sup> cell lines Huh7 and Hep3B and c-Met<sup>+</sup> cell lines MHC...
<p>Cells were treated with the indicated doses of gefitinib, erlotinib, afatinib, or AUY922 for 72 h...
<p>(A) Parental HCC78 and HCC78-TR cells were treated with gefitinib as a single-agent for 3 days an...
<p>(<b>A</b>) Cell viability was assessed following treatment with PF-228 at varying doses for 48 ho...
<p>(A) Phospho-RTK (top) and phospho-kinase (bottom) array analyses performed on untreated parental ...
<p>IC50 for treatment with erlotinib, gefitinib or vandetanib in parental CALU-3 and HCT116 cell lin...
<p>(A) Parental PC9 and gefitinib-resistant PC9 (PC9-GR) cells were treated with gefitinib at the in...
<p>Cells were treated with CX-4945 (5 µM), gefitinib (1 µM), and erlotinib (1 µM) or a combination o...
<p>Cell proliferation in AG1478 (left), gefitinib (middle) and erlotinib (right) was measured by SRB...
<p>(A) Erlotinib-resistant cells (H1650ER) were established by long-term exposure to increasing conc...
<p>HN5 (red), FaDu (blue) and SCC-25 (green) cells were seeded in 96-well plates and treated with th...
<p>A) Representative dose-effect curve plots of HCC827 and HCC4006 parental cell lines to the indica...
PDAC cells were treated with the indicated concentrations of gefitinib for 6 days and cell viability...
<p>(<b>A</b>) BT474, JIMT-1 and MCF7-GFPLC3 cells were treated for 24 h, 72 h and 168 h, respectivel...
<p>The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant cell line H1975 wer...
<p>A) Immunoblot of c-Met<sup>-</sup> cell lines Huh7 and Hep3B and c-Met<sup>+</sup> cell lines MHC...